Farabi Pharmaceutical (XTEH:DFRB1) EBITDA Margin %: 0.00% (As of . 20)


What is Farabi Pharmaceutical EBITDA Margin %?

Farabi Pharmaceutical XTEH:DFRB1 EBITDA Margin % is 0.00% as of . 20.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Farabi Pharmaceutical's EBITDA for the three months ended in . 20 was IRR0.00 Mil. Farabi Pharmaceutical's Revenue for the three months ended in . 20 was IRR0.00 Mil. Therefore, Farabi Pharmaceutical's EBITDA margin for the quarter that ended in . 20 was 0.00%.

Farabi Pharmaceutical  (XTEH:DFRB1) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Farabi Pharmaceutical EBITDA Margin % Related Terms

Farabi Pharmaceutical EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Farabi Pharmaceutical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Farabi Pharmaceutical EBITDA Margin % Chart

Farabi Pharmaceutical Annual Data
Trend
EBITDA Margin %

Farabi Pharmaceutical Quarterly Data
EBITDA Margin %

XTEH:DFRB1 vs IMNPQ, INNV: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Farabi Pharmaceutical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Farabi Pharmaceutical EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Farabi Pharmaceutical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Farabi Pharmaceutical's EBITDA Margin % falls into.


Farabi Pharmaceutical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Farabi Pharmaceutical's EBITDA Margin % for the fiscal year that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (A: . 20 )/Revenue (A: . 20 )
=/
= %

Farabi Pharmaceutical's EBITDA Margin % for the quarter that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Farabi Pharmaceutical (XTEH:DFRB1) has a EBITDA Margin % of 0.00% as of . 20. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Farabi Pharmaceutical and its competitors.
Is Farabi Pharmaceutical's EBITDA Margin % too high?
Farabi Pharmaceutical's current EBITDA Margin % is 0.00%.
How does Farabi Pharmaceutical's EBITDA Margin % compare to IMNPQ and INNV?
Farabi Pharmaceutical's EBITDA Margin % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Farabi Pharmaceutical and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farabi Pharmaceutical's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farabi Pharmaceutical stock overvalued right now?
Farabi Pharmaceutical (XTEH:DFRB1) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Farabi Pharmaceutical (XTEH:DFRB1), the current EBITDA Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Farabi Pharmaceutical Business Description

Address South Kheradmand, No. 45, First Floor, Tehran, IRN, 1584853114
Farabi Pharmaceutical is a pharmaceutical company based in Iran. It produces various oral antibiotic-related and non-antibiotic products and dietary supplements. The company develops anti-migraine, antivirals, cholesterol, diabetic, cardiovascular, gastrointestinal, neuroleptics, anti-prostatic and anti-inflammatory and pain release drugs. It offers products in the form of tablet, capsule and suspensions which include Amoxicillin, Cefixime, Azithromycin, Ciprofloxacin, Nitroglycerin, Repaglinide, Orlistat, Domperidone, among others.